Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 6384 | 1.8202 |
09:33 ET | 203 | 1.8652 |
09:37 ET | 1000 | 1.8422 |
09:39 ET | 11700 | 1.8433 |
09:42 ET | 2369 | 1.88 |
09:44 ET | 1500 | 1.8798 |
09:48 ET | 1562 | 1.9151 |
09:50 ET | 1985 | 1.9 |
09:51 ET | 16414 | 1.84 |
09:53 ET | 13316 | 1.85 |
09:55 ET | 178 | 1.85 |
09:57 ET | 308 | 1.84 |
10:02 ET | 136 | 1.8626 |
10:06 ET | 24534 | 1.91 |
10:08 ET | 400 | 1.895 |
10:13 ET | 5955 | 1.9096 |
10:15 ET | 5300 | 1.89 |
10:18 ET | 11600 | 1.9 |
10:20 ET | 450 | 1.88 |
10:22 ET | 350 | 1.88 |
10:24 ET | 248 | 1.8847 |
10:31 ET | 100 | 1.875 |
10:33 ET | 1418 | 1.875 |
10:36 ET | 400 | 1.86 |
10:45 ET | 7176 | 1.82 |
10:49 ET | 724 | 1.8202 |
10:51 ET | 2770 | 1.8294 |
10:54 ET | 8162 | 1.83 |
10:56 ET | 100 | 1.82 |
10:58 ET | 2351 | 1.8283 |
11:00 ET | 3372 | 1.807623 |
11:02 ET | 100 | 1.8 |
11:05 ET | 967 | 1.77 |
11:07 ET | 100 | 1.77 |
11:09 ET | 100 | 1.77 |
11:12 ET | 938 | 1.79 |
11:14 ET | 10754 | 1.79 |
11:16 ET | 55401 | 1.71 |
11:18 ET | 2100 | 1.7 |
11:21 ET | 100 | 1.6911 |
11:23 ET | 740 | 1.7175 |
11:25 ET | 5000 | 1.7001 |
11:27 ET | 3360 | 1.7096 |
11:30 ET | 6596 | 1.73 |
11:32 ET | 1529 | 1.7399 |
11:34 ET | 200 | 1.74 |
11:36 ET | 4594 | 1.76 |
11:43 ET | 792 | 1.75 |
11:48 ET | 793 | 1.764 |
11:50 ET | 141 | 1.7685 |
11:56 ET | 129 | 1.7565 |
11:57 ET | 216 | 1.7551 |
12:01 ET | 752 | 1.76 |
12:03 ET | 219 | 1.75 |
12:06 ET | 570 | 1.75 |
12:08 ET | 300 | 1.765 |
12:14 ET | 4594 | 1.78 |
12:15 ET | 1882 | 1.76 |
12:17 ET | 449 | 1.77 |
12:19 ET | 2100 | 1.784 |
12:21 ET | 1500 | 1.8 |
12:24 ET | 2545 | 1.8 |
12:26 ET | 500 | 1.786781 |
12:28 ET | 600 | 1.7801 |
12:30 ET | 100 | 1.8 |
12:35 ET | 583 | 1.7985 |
12:37 ET | 3000 | 1.819 |
12:39 ET | 200 | 1.82 |
12:42 ET | 5600 | 1.82 |
12:46 ET | 1300 | 1.82 |
12:48 ET | 809 | 1.8285 |
12:51 ET | 100 | 1.815 |
12:53 ET | 2332 | 1.8229 |
12:55 ET | 100 | 1.8046 |
12:57 ET | 100 | 1.815 |
01:02 ET | 4185 | 1.8003 |
01:09 ET | 200 | 1.7901 |
01:20 ET | 300 | 1.82 |
01:24 ET | 1518 | 1.8 |
01:26 ET | 400 | 1.8199 |
01:58 ET | 100 | 1.79 |
02:00 ET | 200 | 1.799 |
02:07 ET | 1105 | 1.8089 |
02:09 ET | 3602 | 1.7891 |
02:12 ET | 200 | 1.79 |
02:16 ET | 4036 | 1.788 |
02:25 ET | 200 | 1.79 |
02:39 ET | 100 | 1.8 |
02:41 ET | 1252 | 1.7845 |
02:45 ET | 2200 | 1.79 |
02:48 ET | 2830 | 1.7999 |
02:50 ET | 5328 | 1.8291 |
02:52 ET | 5965 | 1.83 |
02:54 ET | 2370 | 1.83 |
02:56 ET | 3000 | 1.84 |
02:59 ET | 1347 | 1.84 |
03:03 ET | 400 | 1.84 |
03:08 ET | 200 | 1.82 |
03:14 ET | 300 | 1.83 |
03:24 ET | 200 | 1.79 |
03:30 ET | 200 | 1.78 |
03:32 ET | 1673 | 1.79 |
03:35 ET | 3396 | 1.79 |
03:42 ET | 892 | 1.79 |
03:44 ET | 600 | 1.79 |
03:46 ET | 3262 | 1.8 |
03:48 ET | 8766 | 1.81 |
03:50 ET | 2430 | 1.81 |
03:51 ET | 10637 | 1.825 |
03:53 ET | 4136 | 1.82 |
03:55 ET | 60818 | 1.75 |
03:57 ET | 44256 | 1.67 |
04:00 ET | 91316 | 1.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 102.4M | -1.7x | --- |
Adlai Nortye Ltd | 114.8M | -0.5x | --- |
Coya Therapeutics Inc | 121.1M | -9.4x | --- |
Assembly Biosciences Inc | 105.3M | -2.2x | --- |
CervoMed Inc | 97.6M | -24.7x | --- |
Century Therapeutics Inc | 119.9M | -0.8x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $112.6M |
---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 60.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.77 |
EPS | $-0.97 |
Book Value | $0.79 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 13.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -582.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.